Cerebral vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 54)
Cerebral logo

Cerebral

ChallengerMental Health Tech

Online Psychiatry & Therapy

Online mental health platform for therapy, medication management, and psychiatry, San Francisco CA, raised $300M+. Serves anxiety, depression, ADHD, and insomnia.

AI VisibilityBeta
Overall Score
C54
Category Rank
#196 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
55
Perplexity
50
Gemini
54

About

Cerebral is a San Francisco, California-based online mental health company founded in 2020 that offers therapy, psychiatric evaluations, and medication management through a telehealth platform. The company raised over $300 million, achieving unicorn status in 2021 during a period of rapid growth, and serves patients with conditions including anxiety, depression, ADHD, insomnia, and bipolar disorder through a subscription-based access model.\n\nCerebral's model is designed to make psychiatric care and therapy more accessible than traditional in-person services by offering online intake, same-week appointments with licensed clinicians, electronic prescriptions, and medication delivery through pharmacy partners. The platform serves both self-pay and insurance-covered patients, having expanded insurance contracting significantly to reduce cost barriers. Cerebral employs a large clinician workforce of therapists and psychiatric nurse practitioners operating across most US states.\n\nThe company navigated a period of regulatory and reputational scrutiny in 2022–2023 related to prescribing practices and marketing claims, which led to leadership changes, workforce restructuring, and a strategic refocus on clinical quality and compliance. Cerebral has since invested in clinical governance infrastructure, stricter prescribing protocols, and transparent outcomes reporting. The company continues to compete with Talkspace, Done, and Done Global in the online psychiatry and therapy market, and has repositioned around a more clinically rigorous, insurance-first approach following the operational challenges of its hypergrowth phase.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
up
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

54
Overall Score
93
#196
Category Rank
#1
80
AI Consensus
80
stable
Trend
up
55
ChatGPT
94
50
Perplexity
89
54
Gemini
94
59
Claude
92
56
Grok
98

Key Details

Category
Online Psychiatry & Therapy
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Cerebral
Online Psychiatry & Therapy

Integrations

Only Pfizer
Pfizer is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.